DPT: Difference between revisions

Line 174:

==Literature==

* ~~Nichols~~, D. E. (~~2016~~). ~~'''''Psychedelics~~.~~''''' ''Pharmacological Reviews''~~, ~~68(2)~~, ~~264~~-~~355~~. ~~https://doi.org/10.1124/pr.115.011478~~

*Soskin, R.A., Grof, S., & Richards, W.A. (1973). Low doses of Dipropyltryptamine in psychotherapy. Archives of General Psychiatry, 28 6, 817-21.

* Richards, W. A., Rhead, J. C., DiLeo, F. B., Yensen, R., & Kurland, A. A. (1977). ~~'''''~~The peak experience variable in DPT-assisted psychotherapy with cancer patients.~~''''' ''~~Journal of Psychedelic Drugs'', 9(1), 1-10. http://dx.doi.org/10.1080/02791072.1977.10472020

* Richards, W. A., Rhead, J. C., DiLeo, F. B., Yensen, R., & Kurland, A. A. (1977). The peak experience variable in DPT-assisted psychotherapy with cancer patients. Journal of Psychedelic Drugs, 9(1), 1-10. http://dx.doi.org/10.1080/02791072.1977.10472020

* Grof, S., Soskin, R. A., Richards, W. A., & Kurland, A. A. (1972). ~~'''''~~DPT as an adjunct in psychotherapy of alcoholics.~~''''' ''~~International Pharmacopsychiatry'', 8(1), 104-115. PMID: 4150711

* Grof, S., Soskin, R. A., Richards, W. A., & Kurland, A. A. (1972). DPT as an adjunct in psychotherapy of alcoholics. International Pharmacopsychiatry, 8(1), 104-115. PMID: 4150711

* ~~Nichols~~, D. E. (~~2004~~). ~~'''''Hallucinogens'''''~~. ''Pharmacology ~~& Therapeutics''~~, ~~101(2)~~, ~~131~~-~~181. https://doi.org/10.1016/j.pharmthera.2003.11~~.~~002~~

*Li, J., Rice, K.C., & France, C.P. (2007). Behavioral effects of dipropyltryptamine in rats: evidence for 5-HT1A and 5-HT2A agonist activity. Behavioural Pharmacology, 18 4, 283-8.

==References==

@@ Line 174: / Line 174: @@
 ==Literature==
-* Nichols, D. E. (2016). '''''Psychedelics.''''' ''Pharmacological Reviews'', 68(2), 264-355. https://doi.org/10.1124/pr.115.011478
+*Soskin, R.A., Grof, S., & Richards, W.A. (1973). Low doses of Dipropyltryptamine in psychotherapy. Archives of General Psychiatry, 28 6, 817-21.
-* Richards, W. A., Rhead, J. C., DiLeo, F. B., Yensen, R., & Kurland, A. A. (1977). '''''The peak experience variable in DPT-assisted psychotherapy with cancer patients.''''' ''Journal of Psychedelic Drugs'', 9(1), 1-10. http://dx.doi.org/10.1080/02791072.1977.10472020
+* Richards, W. A., Rhead, J. C., DiLeo, F. B., Yensen, R., & Kurland, A. A. (1977). The peak experience variable in DPT-assisted psychotherapy with cancer patients. Journal of Psychedelic Drugs, 9(1), 1-10. http://dx.doi.org/10.1080/02791072.1977.10472020
-* Grof, S., Soskin, R. A., Richards, W. A., & Kurland, A. A. (1972). '''''DPT as an adjunct in psychotherapy of alcoholics.''''' ''International Pharmacopsychiatry'', 8(1), 104-115. PMID: 4150711
+* Grof, S., Soskin, R. A., Richards, W. A., & Kurland, A. A. (1972). DPT as an adjunct in psychotherapy of alcoholics. International Pharmacopsychiatry, 8(1), 104-115. PMID: 4150711
-* Nichols, D. E. (2004). '''''Hallucinogens'''''. ''Pharmacology & Therapeutics'', 101(2), 131-181. https://doi.org/10.1016/j.pharmthera.2003.11.002
+*Li, J., Rice, K.C., & France, C.P. (2007). Behavioral effects of dipropyltryptamine in rats: evidence for 5-HT1A and 5-HT2A agonist activity. Behavioural Pharmacology, 18 4, 283-8.
 ==References==